Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2025)

10x Genomics' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 15.03% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $36.2 million, up 0.89%, while the annual FY2025 figure was $36.2 million, 0.89% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $10.1 million at 10x Genomics, down from $10.3 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $10.3 million in Q3 2025 and bottomed at $4.8 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $7.9 million (2025), against an average of $7.7 million.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 58.57% in 2021 before it fell 12.89% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $5.8 million in 2021, then rose by 12.8% to $6.5 million in 2022, then surged by 49.01% to $9.7 million in 2023, then fell by 9.95% to $8.8 million in 2024, then increased by 15.03% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Depreciation & Amortization (CF) are $10.1 million (Q4 2025), $10.3 million (Q3 2025), and $7.8 million (Q2 2025).